Improving Deceased-Donor Kidney Transplant Outcomes Via a Single Intragraft Injection of C1 Esterase Inhibitor: The IMPROVE Trial
| Sponsor: |
National Institute of Allergy and Infectious Diseases NIAID |
| Enrolling: |
Male and Female Patients |
| Study Length: |
3 Years |
| IRB Number: |
ACYY1909 |
| U.S. Govt. ID: |
NCT06919003 |
| Contact: |
Transplant Clinical Research Center: 212-305-3839 / tcrcstudyreferral@cumc.columbia.edu |
This study is testing whether giving an investigational drug called C1 esterase inhibitor (C1INH) directly into the donor kidney before transplant can improve kidney function one year after surgery. At the time of the deceased donor kidney transplant, participants will be randomly assigned to received a kidney that has been treated with either C1INH or a placebo (inactive saline solution). All recipients will continue to receive the standard antirejection medications used after transplant. The study will follow participants regularly for 1 year post-transplant, followed by limited visits up to 3 years post-transplant. If you have any questions regarding this study, please contact the Transplant Clinical Research Center(TCRC).
Investigator
Lloyd Ratner, MD, MPH, FACS
| Are you between 18 to 75 years old? |
Yes |
No |
| Are you on the kidney transplant waiting list? |
Yes |
No |